New safety and efficacy data of the ongoing phase I/II study (ASET Study) with an allogeneic tumor vaccine and adjuvant in patients with metastatic renal cell carcinoma. Background: Recently, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback